Unfortunately, there are still no specific antiviral medicines or vaccines recommended for 2019-nCoV infection. For patients with severe clinical manifestations, an effective clinical treatment scheme is of great importance. On February 7, 2020, the China’s National Health Commission released the fifth trial version of Diagnosis and Treatment Scheme for Pneumonitis with 2019-nCoV Infection, and provided a systematic treatment strategy for severe cases. Remarkably, systematic corticosteroids treatment (methylprednisolone, <1–2 mg per kg body weight, for 3–5 days) was recommended to be an adjuvant therapy3, which immediately raised concerns about whether patients infected with this novel coronavirus could benefit from corticosteroids therapy 4.